Insider Cluster (2 insiders) ·Filed May 16, 2026

APGE

Apogee Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $1.8M total
Actionable Insight • Neutral

The insider sales are too small to be informative. Monitor for any insider buying or material pipeline catalysts (APEX Phase 2 data) that could move the stock. The strong cash runway and bullish analyst consensus suggest the recent offering was well-received.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
APGE ▲ +70.86% at T+60d
NEUTRAL call ✓ call won +70.86% · α vs SPY +66.01% · entry $78.75 → $134.55
Entry anchored
May 15, 2026
via day open
T+1d
-0.61%
call -0.61% · α +0.04%
$78.27
settled 5mo ago
T+5d
+5.16%
call +5.16% · α +3.54%
$82.81
settled 4mo ago
T+20d
+8.24%
call +8.24% · α +6.66%
$85.24
settled 4mo ago
T+60d
+70.86%
call +70.86% · α +66.01%
$134.55
settled 7w ago

Price Chart

Loading chart...

Executive Summary

CEO Michael Thomas Henderson sold $1.53M worth of APGE stock on May 13, 2026, and CMO Carl Dambkowski sold $311K on May 6, totaling $1.84M in insider sales. This cluster follows the company's Q1 2026 earnings release (net loss widened to $74.1M) and a $403M public offering. The sales represent ~0.03% of APGE's $6.3B market cap, a trivial amount, and are likely liquidity-driven post-offering rather than signaling bearish conviction.

Key Financial Metrics

Direction
selling
Total Value
$1.8M
Insiders
2

Key Facts

  • CEO Henderson sold 18,659 shares at $82.05 for $1.53M on May 13, 2026.
  • CMO Dambkowski sold 3,700 shares at $83.92 for $311K on May 6, 2026.
  • Total insider sales of $1.84M represent ~0.03% of APGE's $6.3B market cap.
  • Sales occurred 2-9 days after Q1 2026 earnings (net loss $74.1M, wider than $55.3M YoY) and a $403M public offering.
  • APGE has a strong cash position of $1.3B, extending runway into 2029.
  • Analyst consensus is 83% bullish (19 Buy/10 Strong Buy, 4 Hold).

Financial Impact

Insider sales of $1.84M are trivial relative to $6.3B market cap (0.03%). No material financial impact.

dilution

Risk Factors

  • Widening net loss trajectory (Q1 2026 loss of $74.1M vs. $55.3M YoY) could pressure cash burn if pipeline milestones are delayed.
  • Potential for further dilutive offerings if cash needs increase beyond 2029 runway.
  • Insider selling pattern, while small, may continue post-offering.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-APGE-1778889642156
31 reports for APGE
Performance horizon
93% Hit rate 14 of 15 directional calls best @ T+60▲ +73.31%May 27, 2026
Filters
Rows
Reports for APGE — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
15-12G
NEUTRAL ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
25-NSE
BULLISH ★ 8/10
$135.06 awaiting T+5awaiting T+5——
Sep 3, 2026
29d ago
8-K
BULLISH ★ 8/10
$135.06 awaiting T+5awaiting T+5——
Aug 11, 2026
7w ago
8-K
BULLISH ★ 7/10
$134.55 $134.71▲ +0.12%▲ +0.56%—
Aug 10, 2026
7w ago
8-K
BULLISH ★ 8/10
$134.65 $134.59▼ −0.04%▲ +0.00%—
Aug 10, 2026
7w ago
Press Release
BULLISH ★ 8/10
$134.65 $134.59▼ −0.04%▲ +0.00%—
Aug 6, 2026
8w ago
Institutional Cluster
MIXED ★ 5/10
$134.49 $134.45▼ −0.03%▼ −1.24%—
Aug 3, 2026
8w ago
DEFA14A
BULLISH ★ 5/10
$134.19 $134.69▲ +0.37%▲ +0.47%—
Jul 11, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$133.82 $134.00▲ +0.13%▲ +0.92%—
Jun 26, 2026
13w ago
DEFA14A
BULLISH ★ 6/10
$132.61 $133.50▲ +0.67%▼ −0.72%—
Showing 10 of 31

US Market Status

Market Open — Closes in 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 16, 2026